(Q35215307)

7 August 2017

title

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia (English)

1 reference

7 August 2017

1 reference

1 reference

Brad Spellberg

1

1 reference

7 August 2017

Roger J Lewis

series ordinal

2

1 reference

7 August 2017

Helen W Boucher

series ordinal

3

1 reference

7 August 2017

Eric P Brass

series ordinal

4

1 reference

7 August 2017

publication date

1 January 2011

1 reference

7 August 2017

published in

Clinical investigation

1 reference

7 August 2017

volume

1

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

19-32

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

7 August 2017

1 reference

Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFAPYRIDINE

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Overview of recent studies of community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Determinants for hospitalization in " low-risk" community acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Achieving a safe and early discharge for patients with community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Controlled trials: the 1948 watershed

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Quality of care, process, and outcomes in elderly patients with pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

A prediction rule to identify low-risk patients with community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Comparison of Antibiotics in the Treatment of Mycoplasmal Pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Diagnostic tests for agents of community-acquired pneumonia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Telithromycin and the FDA: implications for the future

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

The FDA and the case of Ketek

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community-acquired pneumonia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173946

Therapeutic effect of doxycycline upon Mycoplasma pneumoniae pneumonia

24 October 2018

1 reference

12 December 2020

The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents

1 reference

12 December 2020

The effect of antibiotics (penicillin, aureomycin, and terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia; a comparison with other methods of therapy

1 reference

12 December 2020

PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA

1 reference

12 December 2020

The United States Food and Drug Administration and the end of antibiotics

1 reference

12 December 2020

Eaton agent pneumonia

1 reference

12 December 2020

Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia

1 reference

12 December 2020

Ketek--the FDA perspective

1 reference

12 December 2020

The long range effect of antibacterial therapy on pneumonia, empyema, bronchiectasis and pulmonary abscess; an analysis of incidence and mortality in 74,489 admissions to a Children's Hospital in twenty years

1 reference

12 December 2020

Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia

1 reference

12 December 2020

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

12 December 2020

Current issues in non-inferiority trials

1 reference

12 December 2020

Factors influencing length of hospital stay in community-acquired pneumonia: a study in 27 community hospitals

1 reference

12 December 2020

Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions

1 reference

12 December 2020

Identifiers

DOI

10.4155/CLI.10.1

1 reference

7 August 2017

1 reference

7 August 2017

1 reference